SAM #36C24526Q0481

High-Plex Proteomic Analysis Services for Prostate Cancer Research at VA Medical Center

The Department of Veterans Affairs, through the Washington DC VA Medical Center and Network Contracting Office 5, is seeking specialized laboratory services for advanced proteomic analysis of blood samples as part of a prostate cancer research initiative. - Government Buyer: - Department of Veterans Affairs - Washington DC VA Medical Center - Network Contracting Office 5 (NCO 5) - Research Department - OEMs and Vendors: - No specific OEMs or vendors are named, but the SomaScan assay platform is specified for the proteomic analysis - Products/Services Requested: - High-plex circulating proteomic profiling using the SomaScan assay platform - Approximately 120 plasma samples from 24 Veterans with advanced metastatic prostate cancer - Services include: receiving coded frozen plasma aliquots, thawing and preparing samples, performing SomaScan assay processing with quality control, and returning standardized proteomic data and quality documentation - General blood sample protein measurement analysis services for clinical research - Unique or Notable Requirements: - Ability to generate reproducible, high-quality proteomic data suitable for biomarker validation and precision oncology research - Experience with high-plex proteomic platforms (specifically SomaScan) - Handling and processing of coded, frozen plasma samples - Delivery of standardized data outputs and quality documentation - Supports a longitudinal study linking proteomic changes to clinical outcomes in Veterans with advanced prostate cancer

Description

The Washington DC VA Medical Center (DC VAMC) is conducting a prospective biospecimen collection and clinical data repository study. Advanced prostate cancer remains a leading cause of cancer morbidity and mortality among Veterans, yet validated circulating biomarkers that predict treatment response or early disease progression are lacking. Current clinical decision-making relies primarily on PSA kinetics and radiographic imaging, which have well-recognized limitations in sensitivity and lead time. The goal of the research study is to generate reproducible, high-quality proteomic data from the study’s longitudinal plasma specimens so that the VA study team can conduct exploratory analyses linking circulating proteomic changes to clinical outcomes, ultimately informing future biomarker validation studies and precision oncology strategies for Veterans with advanced prostate cancer.

View original listing